Extracorporeal blood purification therapies (EBPTs) represent a cornerstone intervention for critically ill patients with acute or chronic organ dysfunction, most notably in nephrology, toxicology, and intensive care settings. This review critically appraises the safety profile of EBPTs, integrating recent research, clinical experience, and current guideline recommendations. It explores the epidemiology, underlying mechanisms, patient-specific risk factors, clinical manifestations of adverse events, diagnostic considerations, and evolving therapeutic strategies to mitigate risk. The article provides practical, evidence-based insights for healthcare professionals, emphasizing the importance of individualized care and multidisciplinary collaboration to optimize patient outcomes while minimizing complications associated with EBPTs.
Extracorporeal blood purification therapies (EBPTs), including hemodialysis, hemofiltration, hemoperfusion, and plasmapheresis, have transformed the management of conditions such as acute kidney injury (AKI), chronic kidney disease (CKD), severe sepsis, and poisoning. While these modalities have demonstrated clear survival and quality-of-life benefits, their safety profile warrants continuous scrutiny due to the potential for serious complications. With technological advances and broader indications for EBPTs, understanding the safety implications remains crucial for both the initiation and ongoing management of these therapies in diverse patient populations.
The global prevalence of conditions necessitating EBPTs has steadily increased. AKI affects up to 20% of hospitalized patients and over 50% of intensive care unit (ICU) patients, of whom 5-10% require renal replacement therapy (RRT). Chronic dialysis is essential for millions worldwide with end-stage renal disease (ESRD). In sepsis, EBPTs are employed for cytokine modulation, and in toxicology, for removal of certain toxins. The expanding use of EBPTs in critical care has led to increased vigilance regarding their safety, with registries and cohort studies reporting complication rates ranging from 15% to over 40%, depending on modality and patient population.
EBPTs function by extracorporeally circulating blood through biocompatible membranes or adsorbent columns, facilitating solute and fluid removal. Despite advancements, contact between blood and artificial surfaces can trigger inflammatory and coagulation cascades, resulting in complement activation, leukocyte adhesion, and microthrombus formation. Hemodynamic instability is frequently observed, especially during rapid volume shifts or solute disequilibrium. In addition, the removal of physiologically essential molecules or medications can precipitate metabolic derangements or therapeutic failures. These mechanisms underscore the importance of understanding the pathophysiology underlying EBPT-related complications to inform preventive and therapeutic strategies.
Risk factors for EBPT-related adverse events are multifactorial. Patient-specific factors include advanced age, comorbid cardiovascular disease, coagulopathy, and hypoalbuminemia. Therapy-related variables such as membrane biocompatibility, anticoagulation strategy, session duration, and ultrafiltration rates also play pivotal roles. Central venous catheterization, commonly required for vascular access, introduces additional risks of infection and thrombosis. The interplay between critical illness severity, immune status, and underlying organ dysfunction further modulates the risk profile, necessitating tailored approaches to risk assessment and management.
Adverse events associated with EBPTs can range from mild to life-threatening. Hypotension remains the most prevalent complication, particularly during intermittent hemodialysis, manifesting as dizziness, syncope, or even cardiac arrest. Bleeding episodes are a significant concern due to anticoagulation, presenting as overt hemorrhage, gastrointestinal bleeding, or intracranial events. Infectious complications, predominantly related to vascular access, may present as fever, chills, sepsis, or localized access site infection. Other clinical manifestations include allergic reactions, arrhythmias, electrolyte imbalances (e.g., hypokalemia, hypophosphatemia), and air embolism. Recognizing these features promptly is critical for timely intervention.
Diagnosis of EBPT-related complications relies on a combination of clinical vigilance and targeted investigations. Continuous hemodynamic monitoring, laboratory assessment of coagulation parameters, serial blood cultures, and imaging studies are routinely employed. Point-of-care ultrasonography aids in the detection of vascular access complications, while advanced monitoring techniques, such as bioimpedance analysis and continuous cardiac output measurement, offer additional safety insights. Multidisciplinary rounds and structured adverse event reporting systems facilitate early recognition and systematic evaluation of EBPT complications.
Management of EBPT-related adverse events depends on the underlying complication. Hypotension is addressed by adjusting ultrafiltration rates, administering intravenous fluids, and modifying dialysate composition. Bleeding warrants reversal or adjustment of anticoagulation, transfusion support, or surgical intervention if indicated. Infections require prompt antibiotic therapy and, if necessary, removal or replacement of vascular access devices. Electrolyte derangements are corrected through individualized dialysate prescriptions and adjunctive supplementation. Proactive measures, such as strict aseptic technique, regular equipment maintenance, and patient education, are integral to minimizing risk.
Technological innovations have substantially enhanced the safety profile of EBPTs. High-flux and biocompatible membranes reduce complement activation and inflammation. Online hemodiafiltration, regional citrate anticoagulation, and adsorption-based cytokine filters represent notable advances in critical care settings. Real-time monitoring systems, including continuous blood volume and temperature sensors, enable rapid detection and correction of adverse events. Artificial intelligence-driven algorithms are being developed to predict complications and optimize therapy parameters in real time, promising further safety improvements in the near future.
International guidelines from organizations such as KDIGO, ESMO, and the Surviving Sepsis Campaign emphasize individualized patient assessment, early identification of at-risk populations, and meticulous attention to procedural detail. Recommendations include the use of biocompatible membranes, judicious anticoagulation, preference for arteriovenous over central venous access when feasible, and implementation of multidisciplinary care pathways. Regular staff training and adherence to standardized protocols are underscored as critical components of safe EBPT delivery.
While EBPTs remain indispensable in the management of a spectrum of life-threatening conditions, their safety profile mandates ongoing vigilance. A thorough understanding of epidemiology, mechanisms of injury, risk stratification, and evidence-based management strategies is crucial for optimizing patient outcomes. Recent technological and procedural advances offer promise in reducing complication rates, but success ultimately hinges on individualized care, multidisciplinary collaboration, and adherence to evolving guidelines. Continuous research and quality improvement initiatives are essential to further enhance the safety and efficacy of EBPTs in clinical practice.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation